Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in PH-ILD Phase 2
NCT00694850Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2008
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riociguat in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by Bayer. Started Aug 2008; status: completed.
02
Drugs
riociguat
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT00694850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694850.